CHAR Tech Welcomes France's Regulatory Advance Opening Biogas Certificate Support to Pyrolysis

This is more important for valuation optionality than for near-term fundamentals. For small-cap project developers like YES/CTRNF, the real asset is not current EBITDA but regulatory eligibility that converts a science project into a financeable pipeline; if France formalizes pyrolysis under CPB, it materially lowers policy risk for future capital raises and project debt. The market usually underprices this kind of “first-country” adoption because the first revenue may be years away, but the multiple can rerate much earlier on de-risking.

Second-order winners are not just CHAR Tech; French EPCs, feedstock aggregators, and offtake counterparties that can anchor long-duration RNG contracts could see a tighter pipeline for low-cost woody feedstock and biocarbon credits. The likely loser is incumbent anaerobic-digestion-heavy RNG developers if subsidy budgets are finite, since a broader eligible-technology set can dilute strike prices and worsen project economics for marginal plants. That said, if CPB is opened without expanding the pot, the benefit may be more political than financial.

The key risk is timing: this is a policy proposal, not a revenue event, and the stock can easily give back any move if legislative adoption or EU state-aid review drags. Over 1-3 months, the catalyst is draft language and ministry follow-through; over 6-18 months, the real test is whether GazoTech reaches FID and financing, because H2 2029 operations are far beyond the market’s normal forecast window. The contrarian view is that the market may be overestimating how much France will subsidize a niche thermochemical pathway versus cheaper biomethane routes, so the thesis dies if the CPB revision excludes pyrolysis or caps support below bankable levels.